OBJECTIVES: To quantify the prognostic importance of prefrailty and frailty in a population-based sample of cancer survivors. DESIGN: The Third National Health and Nutrition Examination Survey mortality-linked prospective cohort study. SETTING: Eighty-nine survey locations across the United States. PARTICIPANTS: Population-based sample of older adults (average age 72.2) with a self-reported diagnosis of nonskin-related cancer (N = 416). MEASUREMENTS: The primary outcome was all-cause mortality. Frailty components included low weight for height, slow walking, weakness, exhaustion, and low physical activity. Participants with none of the five criteria were classified as nonfrail, those with one or two as prefrail, and those with three or more as frail. RESULTS: The prevalence of prefrailty was 37.3% and of frailty was 9.1%. During a median follow-up of 11.2 years, 319 (76.7%) participants died. Median survival was 13.9 years for participants classified as nonfrail, 9.5 years for those classified as prefrail, and 2.5 years for those classified as frail. Cancer survivors classified as prefrail (hazard ratio (HR) = 1.84, 95% confidence interval (CI) = 1.28-2.65, P = .001) or frail (HR = 2.79, 95% CI = 1.34-5.81, P = .006) had a higher risk of premature mortality than those classified as nonfrail. CONCLUSION: Prefrailty and frailty are prevalent clinical syndromes that may confer greater risk of premature mortality in older adult cancer survivors. Identifying frail cancer survivors and targeting interventions for them may be a strategy to improve survival after cancer.
C ancer survivors are living longer after a diagnosis of cancer as a result of earlier detection and efficacious therapies, 1 but many cancer survivors are left with poor global health after receiving the treatments that cured their primary disease, with possible consequences for their longterm prognosis. Frailty is a syndrome of poor global health that includes unintentional weight loss, impaired physical function, weakness, exhaustion, and low levels of physical activity. 2 Frailty is strongly associated with premature mortality in older adults, 2 but the association between frailty and mortality in cancer survivors is unknown. Characterizing the relationship between frailty and mortality may provide insight into the physiological and functional capacity of cancer survivors. 3 Prior studies demonstrate that cancer survivors frequently report symptoms synonymous with frailty 4-8 that may persist for years after completion of treatment for cancer. 9, 10 It has been hypothesized that treatment for cancer accelerates the aging process. 11, 12 Perhaps as a result, cancer survivors are 46% more likely to be frail than adults of similar age without a history of cancer, 3 but given that cancer treatment is a transient exposure, frailty in cancer survivors may represent a unique entity, with etiologies and trajectories distinct from those without a history of cancer. As such, the long-term consequences of prefrailty and frailty in cancer survivors are largely unknown. The hypothesis that prefrailty and frailty confer a greater risk of premature mortality was tested in a nationally representative sample of older community-dwelling cancer survivors.
METHODS

Study Design
The Third National Health and Nutrition Examination Survey, 1988 to 1994 (NHANES III) was a stratified multistage study designed to provide health information on a nationally representative sample of U.S. civilians. All participants provided written informed consent.
Study Participants
Study participants were adults aged 60 and older who selfreported a diagnosis of non-skin-related cancer.
Frailty Definition
A definition of frailty that has been operationalized previously in the NHANES III database was used. 13 The five criteria for frailty were low weight for height (body mass index (BMI) ≤18.5 kg/m 2 ); slow walking speed (defined using the slowest quintile, adjusted for sex, in a timed 2.4-m walk); weakness (having any level of difficulty or inability to lift or carry something as heavy as 4.5 kg); exhaustion (having any level of difficulty or inability to walk from one room to another on the same floor); low levels of physical activity (self-report of being less active than men or women of similar age). Participants with none of the five criteria were classified as nonfrail, those with one or two as prefrail, and those with three or more as frail. 13 
Mortality Outcome
The primary outcome of this study was all-cause mortality. Vital status was identified using the National Death Index database through December 31, 2006. Participants were linked to the database using a probabilistic matching algorithm that included 12 identifiers, including Social Security Number, sex, date of birth, race, state of residence and birth, and marital status. 14 The National Center for Health Statistics removed select subject characteristics in the file to prevent the re-identification of study participants. The publically released survival data are nearly identical to those in the restricted-use NHANES III linked mortality file. 15 
Covariates
Demographic information including date of birth and sex were self-reported using a standardized questionnaire. Clinical information including type of cancer, date of cancer diagnosis, smoking history, alcohol consumption, hospitalizations in the prior year, self-reported health status, and frequency of physical activity were assessed using a standardized questionnaire. Cognitive function was assessed using the short portable version of the Mini-Mental State Examination. 16 The presence of comorbid health conditions was determined by asking participants whether a doctor had ever told them that they had hypertension, diabetes mellitus, hyperlipidemia, asthma, arthritis, myocardial infarction, stroke, or congestive heart failure.
Study technicians measured height in meters and weight in kilograms and calculated body mass index as weight divided by the square of height (kg/m 2 ). Hemoglobin was quantified using an electronic counter (S-Plus Jr.; Coulter Electronics, Hialeah, FL). Albumin was quantified using a multichannel analyzer (Hitachi 737; Boehringer Mannheim Diagnostics, Indianapolis, IN). C-reactive protein was determined using latex-enhanced nephelometry immunoassay (Behring Diagnostics, Somerville, NJ). Plasma fibrinogen was measured using enzyme assay methods (Coag-A-Mate XC plus, Scarborough, ON, Canada).
Statistical Analysis
Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Log-log plots were examined to confirm the assumption of proportional hazards. Sample weights were incorporated into the statistical analyses to account for nonresponse bias, and multistage sampling probabilities were used to provide estimates for the U.S. population. Stata/SE version 13.1 statistical software (Stata Corp., College Station, TX) was used for all analyses. Additional exploratory analysis methods are presented in the Data S1.
RESULTS
Four hundred ninety-eight adults aged 60 and older who self-reported a prior diagnosis of non-skin-related cancer were identified, and sufficient information was available on 416 (84%) to define frailty. Participants with insufficient information necessary to define frailty were more likely to have arthritis (63.3% vs 45.2%; P = .02), lower albumin (3.9 vs 4.0 g/dL; P = .01), and poorer self-reported health (3.5 vs 3.0; P = .004) than those with sufficient information necessary to define frailty. No other differences were observed between participants with and without sufficient information necessary to define frailty.
Cohort Characteristics
The mean age of study participants was 72.2, and 61.0% were female (Table 1) . Participants were diagnosed with cancer at a variety of sites, including breast (26.3%), gastrointestinal (18.4%), genitourinary (21.3%), gynecological (14.2%), lung (2.7%), and hematological (2.5%). The mean time since cancer diagnosis was 11.2 years, and 34.2% were less than 5 years, 21.5% were 5 to 9 years, and 44.3% were 10 or more years since cancer diagnosis.
Characteristics Associated with Mortality
In 416 participants, 319 deaths (76.7%) were observed during a median of 11.2 years of follow-up (Table 1) . Participants who died during follow-up were more likely to be older; male; diagnosed with gastrointestinal, genitourinary, or lung cancer; have poorer cognitive function; report a history of myocardial infarction or stroke; have higher concentrations of C-reactive protein; and self-report poorer health than those who did not die during followup. Time since cancer diagnosis, measured as a continuous or categorical variable, was not associated with mortality.
Prevalence and Prognostic Importance of Individual Frailty Criteria
The prevalence of the individual criteria for frailty ranged from 3.7% to 29.2% (Table 1) . When each of the five frailty criteria was individually entered into a multivariable-adjusted model, low weight for height, weakness, and low physical activity were associated with premature mortality ( were independently associated with premature mortality ( Table 2) . A relationship was found between the number of frailty components treated as an ordinal (count) variable (P trend < .001) and as a continuous variable (HR = 1.46, 95% CI = 1.22-1.73, P < .001) with the risk of premature mortality (Table S1 ).
Prevalence and Prognostic Importance of Prefrailty and Frailty
The prevalence of prefrailty was 37.3% and of frailty was 9.1% (Table 1) . Median survival was 9.5 years in participants classified as prefrail, 2.5 years in those classified as frail, and 13.9 years in those classified as nonfrail (Figure 1) . Participants classified as prefrail or frail had a significantly greater risk of premature mortality than those who were nonfrail ( Table 2) .
Discriminative Characteristics of Frailty to Predict 5and 10-Year Mortality
The discriminative characteristics of frailty to predict 5and 10-year mortality are presented in Tables S2 and S3 and Figure S1 . The addition of frailty to a model that included age, sex, and type of cancer significantly improved the area under the receiver operating curve to predict 5-year (0.76 vs 0.71, P = .009) and 10-year (0.80 vs 0.77, P = .006) mortality.
DISCUSSION
In this cohort of older adult cancer survivors, prefrailty and frailty conferred greater risk of premature mortality. Because frailty is likely to be related to aging and to cancer treatments, providers should be aware of this syndrome and its consequences in older cancer survivors. 17 Although screening to identify frail older adults has increased in oncological practice, such screening most often occurs before the initiation of cancer treatment to identify individuals who are vulnerable to treatment-related toxicity. 18 Less focus has been paid to the effect of frailty after the completion of cancer treatment. The results from this study suggest that screening for the presence of prefrailty or frailty in older adults who are cancer survivors may lead to greater insight into long-term prognosis. Previous studies have demonstrated that frailty is highly prevalent in older adults with cancer and is proba- Figure 1 . Kaplan-Meier survival plot stratified according to stage of frailty. Frailty components included low weight for height, slow walking, weakness, exhaustion, and low physical activity. Participants classified as nonfrail had no frailty components, those classified as prefrail had one or two, and those classified as frail had three or more.
bly more common than in the general older population. A systematic review of 21 studies of frailty in populations of community-dwelling older adults reported that the mean prevalence of frailty was 9.9% (range 4-59%). 19 In contrast, a systematic review of 20 studies of older adults with cancer found that the median prevalence of frailty was 42% (range 6-86%). 20 Although the fact that they have survived cancer and its therapies may label older cancer survivors as uniquely robust older adults, studies have shown that older cancer survivors routinely report higher rates of decline in functional status and overall health in the years after their cancer diagnosis than age-matched controls without cancer. 21, 22 It has been hypothesized that this accelerated deterioration of functional status and overall health is related to cancer treatments, 21, 22 which underscores the importance of studying frailty in this unique population.
A strong association was found between postcancer frailty and mortality, which may indicate that the presence of frailty after cancer treatment heralds future adverse health events or poorer quality of life for older cancer survivors. Given the likely dynamic changes in health that result from cancer and cancer therapy, older adults with cancer may benefit from being monitored before and after treatment for the identification of early frailty symptoms. Experts agree that, in the absence of early identification and intervention, prefrail older adults inevitably progress to frailty 2 and that frail older adults will continue a trajectory of worsening health. 23 Intervention efforts that prevent or delay the onset of frailty are needed to avoid these outcomes in cancer survivors. 11 Exercise or physical activity may be an efficacious lifestyle intervention for older adult cancer survivors with or at risk of frailty. 24 Regular physical activity, such as brisk walking, may reduce frailty in older adults at risk of disability. 25 Exercise may also improve gait speed, balance, and self-reported activities of daily living in frail adults. 26 Exercise in cancer survivors may improve self-reported outcomes, 27 and observational studies suggest that exercise may reduce the risk of cancer-specific and all-cause mortality. 28 Additional research is warranted to better characterize the safety and efficacy of exercise in older adult cancer survivors.
There are limitations to this study. The modified definition of frailty, based on the definition operationalized by Fried and colleagues, 2 was necessary to accommodate the data available in the nationally representative NHANES III database, although this modified definition has been used and validated in prior reports of NHANES. 13, 29 There are other approaches that may be used in clinical practice to identify older adult cancer survivors at risk of poor outcomes. For example, the Comprehensive Geriatric Assessment may provide useful clinical guidance in geriatric oncology 17 and may inform the care of older adults with cancer by identifying impairments that are amenable to intervention and predict the risk of adverse outcomes such as treatment-related toxicity, functional or cognitive decline, postoperative complication, and overall survival. 30 Another limitation of this analysis is the inability to identify incident cases of frailty. Therefore, it is conceivable that some of the study subjects may have become prefrail or frail before cancer diagnosis or treatment, although the study focused on metrics obtained after cancer diagnosis, and the data suggest that prefrailty and frailty are prevalent in cancer survivors and confer greater risk of premature mortality. Information was not available regarding stage of cancer or specific cancer treatments received. It is likely that these covariates attenuated the association between frailty and mortality.
This study has several strengths. As a result of the sampling framework of NHANES, the study cohort was a nationally representative sample of community-dwelling older adult cancer survivors in the United States. The study had an extensive median length of follow up of 11.2 years, which allowed a high proportion of deaths to be observed. A variety of covariates that may confound the association between frailty and mortality were accounted for, including demographic, clinical, and blood chemistry measures.
In conclusion, prefrailty and frailty are prevalent clinical syndromes that confer greater risk of premature mortality in older cancer survivors. These findings demonstrate the need for additional research in the area of geriatric oncology. Frailty screening tools should be validated in cohorts of cancer survivors to inform clinical decisionmaking and characterize the etiologies and trajectories of frailty in this population. 3 Efficacious interventions are also needed to prevent or delay the onset of frailty. Exercise or physical activity is a promising intervention, with many possible benefits for older cancer survivors. Randomized studies are necessary to determine whether exercise can delay or prevent the onset of incident frailty in this population. This knowledge will help to improve the quality and quantity of cancer survivorship.
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